22
Participants
Start Date
October 27, 2017
Primary Completion Date
August 20, 2019
Study Completion Date
April 21, 2020
adalimumab
Study drug will be administered subcutaneously.
Yamaguchi University Hospital /ID# 164562, Ube-shi
Nagoya City University Hospital /ID# 164510, Nagoya
Juntendo University Urayasu Hospital /ID# 164422, Urayasu Shi
Fukuoka University Hospital /ID# 164416, Fukuoka
Fukushima Medical University Hospital /ID# 164358, Fukushima
Gunma University Hospital /ID# 164464, Maebashi
Asahikawa Medical University Hospital /ID# 164589, Asahikawa-shi
Showa University Fujigaoka Hospital /ID# 164406, Yokohama
Mie University Hospital /ID# 164389, Tsu
Tohoku University Hospital /ID# 164360, Sendai
Shinshu University Hospital /ID# 164852, Matsumoto-shi
Nagasaki University Hospital /ID# 167604, Nagasaki
University of the Ryukyus Hospital /ID# 164981, Nakagami-gun
Hamamatsu University Hospital /ID# 165890, Hamamatsu
Tokushima University Hospital /ID# 164359, Tokushima
Teikyo University Hospital /ID# 165665, Itabashi-ku
Tokyo Medical University Hospital /ID# 165810, Shinjuku-ku
Keio University Hospital /ID# 165680, Shinjuku-ku
Kansai Medical Univ Hosp /ID# 165802, Hirakata-shi, Osaka
Hokkaido University Hospital /ID# 164419, Sapporo
Lead Sponsor
AbbVie
INDUSTRY